Filtered By:
Source: Oncotarget

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 624 results found since Jan 2013.

Peptide-siRNA nanotherapeutics in arthritis.
Authors: Pham CT, Pan H, Wickline SA PMID: 26121712 [PubMed - as supplied by publisher]
Source: Oncotarget - July 2, 2015 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Validation of a network-based strategy for the optimization of combinatorial target selection in breast cancer therapy: siRNA knockdown of network targets in MDA-MB-231 cells as an in vitro model for inhibition of tumor development.
Authors: Tilli TM, Carels N, Tuszynski JA, Pasdar M Abstract Network-based strategies provided by systems biology are attractive tools for cancer therapy. Modulation of cancer networks by anticancer drugs may alter the response of malignant cells and/or drive network re-organization into the inhibition of cancer progression. Previously, using systems biology approach and cancer signaling networks, we identified top-5 highly expressed and connected proteins (HSP90AB1, CSNK2B, TK1, YWHAB and VIM) in the invasive MDA-MB-231 breast cancer cell line. Here, we have knocked down the expression of these proteins, individua...
Source: Oncotarget - August 18, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
Authors: McCarroll JA, Dwarte T, Baigude H, Dang J, Yang L, Erlich RB, Kimpton K, Teo J, Sagnella SM, Akerfeldt MC, Liu J, Phillips PA, Rana TM, Kavallaris M Abstract Non-small cell lung cancer (NSCLC) remains the most common cause of cancer death worldwide due its resistance to chemotherapy and aggressive tumor growth. Polo-like kinase 1 (PLK1) is a serine-threonine protein kinase which is overexpressed in cancer cells, and plays a major role in regulating tumor growth. A number of PLK1 inhibitors are in clinical trial; however, poor tumor bioavailability and off-target effects limit their efficacy. Short-interfer...
Source: Oncotarget - January 10, 2015 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Biocompatible and colloidally stabilized mPEG-PE/calcium phosphate hybrid nanoparticles loaded with siRNAs targeting tumors.
Authors: Gao P, Zhang X, Wang H, Zhang Q, Li H, Li Y, Duan Y Abstract Calcium phosphate nanoparticles are safe and effective delivery vehicles for small interfering RNA (siRNA), as a result of their excellent biocompatibility. In this work, mPEG-PE (polyethylene glycol-L-α-phosphatidylethanolamine) was synthesized and used to prepare nanoparticles composed of mPEG-PE and calcium phosphate for siRNA delivery. Calcium phosphate and mPEG-PE formed the stable hybrid nanoparticles through self-assembly resulting from electrostatic interaction in water. The average size of the hybrid nanoparticles was approximately 53.2...
Source: Oncotarget - December 5, 2015 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Efficient delivery of small interfering RNAs targeting particular mRNAs into pancreatic cancer cells inhibits invasiveness and metastasis of pancreatic tumors.
We report the use of small interfering RNAs (siRNAs) against ARHGEF4, CCDC88A, LAMTOR2, mTOR, NUP85, and WASF2 and folic acid (FA)-modified polyethylene glycol (PEG)-chitosan oligosaccharide lactate (COL) nanoparticles for targeting, imaging, delivery, gene silencing, and inhibition of invasiveness and metastasis in an orthotopic xenograft model. In vitro assays revealed that these siRNA-FA-PEG-COL nanoparticles were specifically inserted into pancreatic cancer cells compared to immortalized normal pancreatic epithelial cells and knocked down expression of the corresponding targets in pancreatic cancer cells. Cell motility...
Source: Oncotarget - May 15, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Long non-coding RNA ANRIL promotes the invasion and metastasis of thyroid cancer cells through TGF- β/Smad signaling pathway.
CONCLUSIONS: ANRIL may reduce p15INK4B expression through inhibiting TGF-β/Smad signaling pathway, promoting invasion and metastasis of TC cells, and the silencing of ANRIL inhibits the invasion and metastasis of TPC-1 cells. PMID: 27507052 [PubMed - as supplied by publisher]
Source: Oncotarget - August 13, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

YAP promotes erlotinib resistance in human non-small cell lung cancer cells.
Authors: Hsu PC, You B, Yang YL, Zhang WQ, Wang YC, Xu Z, Dai Y, Liu S, Yang CT, Li H, Hu B, Jablons DM, You L Abstract Yes-associated protein (YAP) is a main mediator of the Hippo pathway, which promotes cancer development. Here we show that YAP promotes resistance to erlotinib in human non-small cell lung cancer (NSCLC) cells. We found that forced YAP overexpression through YAP plasmid transfection promotes erlotinib resistance in HCC827 (exon 19 deletion) cells. In YAP plasmid-transfected HCC827 cells, GTIIC reporter activity and Hippo downstream gene expression of AREG and CTGF increased significantly (P<0.0...
Source: Oncotarget - July 15, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

MicroRNA-21 promotes TGF- β1-induced epithelial-mesenchymal transition in gastric cancer through up-regulating PTEN expression.
This study aimed to explore the effects of miR-21 and PTEN/Akt signaling pathway on TGF-β1-induced epithelial-mesenchymal transition (EMT) in gastric cancer (GC). GC tissues and adjacent tissues were collected from 83 patients. The qRT-PCR assay was performed to detect miR-21 expression. The expressions of PTEN, Akt and p-Akt were detected by immunohistochemistry. After 48 h of treatment with TGF-β1 (10 ng/mL), the SGC-7901 and KATO-III cells were divided into the blank, negative control (NC), miR-21 inhibitors, PTEN-siRNA and miR-21 inhibitors + PTEN-siRNA groups. EMT related factors and PTEN expressions were detected b...
Source: Oncotarget - September 11, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

STAT3 regulates glycolysis via targeting hexokinase 2 in hepatocellular carcinoma cells.
This study examined whether STAT3 regulates HCC glycolysis through the HK2 pathway in HCC cells. Human HCC cell lines HepG2 and Hep3B cells were transfected with pcDNA3.1(+)-EGFP-STAT3, STAT3 siRNA and HK2 siRNA, respectively, or treated with rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), and the effects on STAT3 and HK2 expression and cell glycolysis were determined. STAT3 and HK2 expressions were evaluated by real-time polymerase chain reaction and Western blotting. The level of glycolysis metabolism was assessed by the determination of glucose consumption and lactate production.The results showed that ...
Source: Oncotarget - April 29, 2017 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

STAT3 inhibition suppresses proliferation of retinoblastoma through down-regulation of positive feedback loop of STAT3/miR-17-92 clusters.
In conclusion, we suggest that STAT3 inhibition could be a potential therapeutic approach in retinoblastoma through the suppression of tumor proliferation. PMID: 25359779 [PubMed - as supplied by publisher]
Source: Oncotarget - November 12, 2014 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

P62 regulates resveratrol-mediated Fas/Cav-1 complex formation and transition from autophagy to apoptosis.
In conclusion, P62 links resveratrol-induced autophagy to apoptosis. P62 blocks apoptosis by inhibiting Fas/Cav-1 complex formation, but RSV-induced autophagic degradation of P62 enables formation of Fas/Cav-1 complexes which then activate caspase-8-mediated Beclin-1 cleavage, resulting in translocation of the Beclin-1 C-terminal fragment to the mitochondria to initiate apoptosis. PMID: 25596736 [PubMed - as supplied by publisher]
Source: Oncotarget - January 21, 2015 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Cancerous inhibitor of protein phosphatase 2A contributes to human papillomavirus oncoprotein E7-induced cell proliferation via E2F1.
In this study, we demonstrated that HPV-16E7 protein significantly upregulating CIP2A mRNA and protein expression depended on retinoblastoma protein pRb rather than p130. CIP2A siRNA knockdown in HPV-E7-expressing cells inhibited cell proliferation, DNA synthesis and G1/S cell cycle progression. CIP2A siRNA decreased the protein levels of cyclin-dependent kinase 1 (Cdk1), Cdk2 and their partner cyclin A2, with no change in levels of Cdk4, Cdk6 and their partner cyclin D1. The downregulation of Cdk1 and Cdk2 was independent of c-Myc; instead, E2F1 was the main target of CIP2A in this process, as overexpression of E2F1 rescu...
Source: Oncotarget - February 6, 2015 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120).
This study thus provides a proof-of-concept for the use of in vitro siRNA screening to explore the EMT-related functions of selected genes and their potential relevance in the discovery of EMT reversing drugs. PMID: 26061747 [PubMed - as supplied by publisher]
Source: Oncotarget - June 12, 2015 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

siRNAs with decreased off-target effect facilitate the identification of essential genes in cancer cells.
Authors: Li C, Liu Z, Yang F, Liu W, Wang D, Dong E, Wang Y, Wu CI, Lu X Abstract Since the essential genes are crucial to the proliferation and survival of cancer cells, the interference of these genes is promising to be an option for cancer therapy to overcome heterogeneity. However, the essential genes are highly overestimated by RNA interference (RNAi) screenings, which is mainly caused by the pervasive off-target effect of small interference RNA (siRNA) and short hairpin RNA (shRNA). In the present study, we designed Match-Mismatch paired siRNAs to discriminate the on-target effect from off-target effect of si...
Source: Oncotarget - June 12, 2015 Category: Cancer & Oncology Tags: Oncotarget Source Type: research